EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Direct in vivo CAR T cell engineering

Lauralie Short, Robert A Holt, Pieter R Cullis, Laura Evgin

Trends in Pharmacological Sciences · 2024-05 · 45 (5) · 406-418

DOI: 10.1016/j.tips.2024.03.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2024-05. Verfasst von Lauralie Short und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of Brit…. Hauptthemen laut MEDLINE: T-Lymphocytes, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BC Cancer Foundation, Michael Smith Foundation for Health Research, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cells modified to express intelligently designed chimeric antigen receptors (CARs) are exceptionally powerful therapeutic agents for relapsed and refractory blood cancers and have the potential to revolutionize therapy for many other diseases. To circumvent the complexity and cost associated with broad-scale implementation of ex vivo manufactured adoptive cell therapy products, alternative strategies to generate CAR T cells in vivo by direct infusion of nanoparticle-formulated nucleic acids or engineered viral vectors under development have received a great deal of attention in the past few years. Here, we outline the ex vivo manufacturing process as a motivating framework for direct in vivo strategies and discuss emerging data from preclinical models to highlight the potency of the in vivo approach, the applicability for new disease indications, and the remaining challenges associated with clinical readiness, including delivery specificity, long term efficacy, and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesReceptors, Chimeric AntigenImmunotherapy, AdoptiveHumansAnimalsCell EngineeringReceptors, Antigen, T-CellNeoplasms

Stichwörter der Autor:innen

DNAchimeric antigen receptorengineered lentivirusesin vivo cell therapylipid nanoparticlesmRNApolymer nanoparticles

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
  • Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada; Department of Medical Genetics, U…
  • Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada.

Förderung

  • BC Cancer Foundation
  • Michael Smith Foundation for Health Research
  • CIHR
  • BC Cancer Agency

Zitieren

APA

Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024). Direct in vivo CAR T cell engineering. Trends in Pharmacological Sciences, 45(5), 406-418. https://doi.org/10.1016/j.tips.2024.03.004

Vancouver

Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends in Pharmacological Sciences. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

BibTeX
@article{Short2024,
  author = {Short, Lauralie and Holt, Robert A and Cullis, Pieter R and Evgin, Laura},
  title = {Direct in vivo CAR T cell engineering},
  journal = {Trends in Pharmacological Sciences},
  year = {2024},
  volume = {45},
  number = {5},
  pages = {406--418},
  doi = {10.1016/j.tips.2024.03.004}
}
Kostenlos starten →